Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy
Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy
复制标题
对精神分裂症神经代谢物水平的治疗效果：质子磁共振波谱的荟萃分析数据集
DOI：
10.1016/j.dib.2020.105862
复制
发表时间：
2020
期刊：
影响因子：
1.2
通讯作者：
Horita Nobuyuki
中科院分区：
文献类型：
--
作者：
Kubota Manabu;Moriguchi Sho;Takahata Keisuke;Nakajima Shinichiro;Horita Nobuyuki
本文描述了一项荟萃分析的数据集，旨在研究治疗对精神分裂症患者神经代谢物状态的影响（原始文章的DOI：https://doi.org/10.1016/j.schres.2020.03.069 [1]）。使用MEDLINE、Embase和PsycINFO进行数据检索。研究的神经代谢物包括谷氨酸、谷氨酰胺、谷氨酸+谷氨酰胺、γ-氨基丁酸、N-乙酰天冬氨酸和肌醇，感兴趣区域（ROI）包括额叶皮质、颞叶皮质、顶枕叶皮质、丘脑、基底神经节和海马。采用随机效应模型进行荟萃分析，并在三个或更多患者组的每个ROI中使用受试者治疗前和治疗后神经代谢物的标准化平均差异法。该数据集涵盖了39个患者组（随访时的773名精神分裂症患者）的原始数据，治疗前后均通过磁共振波谱法测量神经代谢物水平。此外，它还包含每组的临床特征和治疗类型的详细信息。因此，这些数据将有助于从不同的角度重新研究治疗对神经代谢物状态的影响，以及制定未来的精神疾病治疗策略。
This article describes a dataset for a meta-analysis that aimed to investigate the effects of treatment on the neurometabolite status in patients with schizophrenia (DOI of original article: https://doi.org/10.1016/j.schres.2020.03.069 [1]). The data search was performed with MEDLINE, Embase, and PsycINFO. The neurometabolites investigated include glutamate, glutamine, glutamate + glutamine, gamma-aminobutyric acid,N-acetylaspartate, and myo-inositol, and the regions of interest (ROIs) include the frontal cortex, temporal cortex, parieto-occipital cortex, thalamus, basal ganglia, and hippocampus. The meta-analysis was conducted with a random-effects model, and the use of the standardized mean difference method between pre- and post-treatment of subjects for neurometabolites in each ROI of three patient groups or more. The dataset covers raw data of 39 patient groups (773 patients with schizophrenia at follow-up) with neurometabolite levels measured by magnetic resonance spectroscopy both before and after treatment. Furthermore, it contains details of clinical characteristics and treatment types for each group. Therefore, the data would be useful for a reinvestigation of treatment effects on the neurometabolite status from diverse points of view, as well as for the development of future treatment strategies for psychiatric diseases.